Drugs News and Research

RSS

Super-resolution microscopy technique reveals how and why cell's defenses fail against plague

Researchers at Sandia National Laboratories have developed a super-resolution microscopy technique that is answering long-held questions about exactly how and why a cell's defenses fail against some invaders, such as plague, while successfully fending off others like E.coli.

17 May 2011

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study conducted globally by American and French researchers.

17 May 2011

Abcc10 might help counter resistance and extend effectiveness of anticancer drugs

Today's anticancer drugs often work wonders against malignancies, but sometimes tumors become resistant to the effects of such drugs, and treatment fails. Medical researchers would like to find ways of counteracting such resistance, but first they must understand why and how it happens.

17 May 2011

FDA nod for hepatitis C drug

Merck & Co have finally won the Food and Drugs Administration – FDA’S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.

17 May 2011

Opinion: New HIV infections more expensive than providing antiretroviral drugs to existing patients

In light of study findings released last week showing the risk of HIV transmission can be reduced by 96 percent if HIV-positive patients begin combination antiretroviral therapy as soon as possible, a San Francisco Chronicle editorial asks, "The evidence is clearly starting to show that it's much better to treat patients earlier, but from where will the money come?".

17 May 2011

FDA warns consumers about look like antimicrobial dietary supplements

The FDA is warning consumers not to use products marketed as dietary supplements that also claim to be antimicrobial (antibiotic, antifungal or antiviral) drugs. These illegal products are falsely promoted with claims to treat illnesses such as upper respiratory infections, sinusitis, pneumonia, bronchitis and the common cold.

16 May 2011

InVivo Therapeutics reports net loss of $1,278,000 for first quarter 2011

InVivo Therapeutics, a medical device company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today reported financial results for the first quarter 2011.

16 May 2011

Study finds no potential cardiovascular risks of ADHD medications in children, adolescents

Despite recent concerns that medications for attention deficit hyperactivity disorder could increase the risk of cardiovascular events in children and adolescents, an observational study conducted by researchers at the University of Pennsylvania School of Medicine and HealthCore Inc. finds they are no more likely to die from a severe cardiovascular event than those who do not take the drugs.

16 May 2011

Study: HIV treatment drugs slash transmission risk

AIDS researchers offered evidence backing up the long-standing idea that people infected with HIV who are being treated are much less likely to transmit the virus than those who are not on drugs. This finding is being hailed as a breakthrough.

16 May 2011

Synexus completes CT327 phase II psoriasis trial for Creabilis

Synexus has completed a phase II study for the European biotech, Creabilis, recruiting 26 patients in the UK to the psoriasis trial of its CT327 lead product in just 2 weeks, as part of an international proof-of-concept study. The company delivered the targeted number of patients well within the agreed timelines and budget.

From AES - Accelerated Enrollment Solutions 16 May 2011

Counterfeit medicines posing increasing risk to patients worldwide, U.N. agency says

Counterfeit medications are posing an increasing threat to patients' health worldwide, because they offer high returns and low risks for criminal organizations, the U.N. Office on Drugs and Crime said in a statement on Friday, Agence France-Presse reports.

16 May 2011

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Substances produced by living organisms found in nature-so-called "natural products"-have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

16 May 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Preliminary results from a multicountry clinical trial, sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), show that HIV-positive people who take combination antiretroviral therapy (ART) can reduce the risk of transmitting the virus to their HIV-negative partners by 96 percent, U.S. researchers announced on Thursday " in what is being hailed as a breakthrough in HIV prevention," the Los Angeles Times reports.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).

16 May 2011

Study reveals crucial role of histone deacetylases in type 2 diabetes

A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.

16 May 2011

Scientists discover new class of compounds that selectively block 'serine hydrolases'

Scientists from The Scripps Research Institute have identified a class of compounds that could be a boon to basic research and drug discovery.

16 May 2011

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.

16 May 2011

Teva signs definitive agreement to acquire Taiyo

Teva Pharmaceutical Industries Ltd. announced today that it has signed a definitive agreement to acquire 57% of the shares in privately-held Taiyo Pharmaceutical Industry Co. Ltd. for $460 million in cash paid to private shareholders.

16 May 2011

Obese men may face high risk of prostate cancer progression

Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers at Duke University Medical Center have found.

16 May 2011

Drugs News and Research

Super-resolution microscopy technique reveals how and why cell's defenses fail against plague

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

Abcc10 might help counter resistance and extend effectiveness of anticancer drugs

FDA nod for hepatitis C drug

Opinion: New HIV infections more expensive than providing antiretroviral drugs to existing patients

FDA warns consumers about look like antimicrobial dietary supplements

InVivo Therapeutics reports net loss of $1,278,000 for first quarter 2011

Study finds no potential cardiovascular risks of ADHD medications in children, adolescents

Study: HIV treatment drugs slash transmission risk

Synexus completes CT327 phase II psoriasis trial for Creabilis

Counterfeit medicines posing increasing risk to patients worldwide, U.N. agency says

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Study reveals crucial role of histone deacetylases in type 2 diabetes

Scientists discover new class of compounds that selectively block 'serine hydrolases'

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Teva signs definitive agreement to acquire Taiyo

Obese men may face high risk of prostate cancer progression

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News